| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -6,668 | -28,235 |
| Depreciation and amortization | 11,207 | 7,178 |
| Amortization of intangible assets | 2,525 | 1,683 |
| Reduction in the carrying value of right-of-use assets | 6,193 | 4,077 |
| Non-cash interest expense | 208 | 139 |
| Deferred tax benefit | -6,129 | -2,292 |
| Provision recorded for credit losses | 5,403 | 3,116 |
| Loss on disposal of property and equipment | -73 | -44 |
| Adjustment for excess and obsolete inventories | -7,963 | -6,093 |
| Stock-based compensation | 8,974 | 5,909 |
| Write-down to fair value for asset held for sale (note 6) | 9,235 | 8,313 |
| Accounts receivable | 64,325 | 13,637 |
| Inventories | 14,954 | 15,892 |
| Prepaid expenses and other current assets and other assets | 3,298 | 12,942 |
| Operating leases | 6,302 | 4,147 |
| Accounts payable | 643 | 1,637 |
| Accrued expenses and other current liabilities | -1,943 | -13,886 |
| Other liabilities | 1,466 | 34 |
| Net cash provided by (used in) operating activities | -49,729 | -52,808 |
| Purchases of property and equipment | 9,499 | 7,264 |
| Net cash used in investing activities | -9,499 | -7,264 |
| Landlord assets under construction, net of tenant allowance | 10,039 | - |
| Payments of withholding taxes in connection with rsus vesting | 1,798 | 1,796 |
| Proceeds from the exercise of stock options | 155 | 25 |
| Principal repayments of finance lease obligations | 869 | 573 |
| Net cash used in financing activities | -12,551 | -2,344 |
| Change in cash, cash equivalents and restricted cash | -71,779 | -62,416 |
| Cash and cash equivalents at beginning of period | 136,151 | - |
| Cash and cash equivalents at end of period | 64,372 | - |
Organogenesis Holdings Inc. (ORGO)
Organogenesis Holdings Inc. (ORGO)